Saturday - October 18, 2025
Compared to Standard of Care: Phase 3 MajesTEC-3 Study Reveals TECVAYLI Plus DARZALEX FASPRO Combination Significantly Improves PFS, Overall Survival
October 17, 2025
NORTH HOLLYWOOD, California, Oct. 17 (TNSrep) -- The International Myeloma Foundation issued the following news on Oct. 16, 2025:

* * *

Compared to Standard of Care: Phase 3 MajesTEC-3 study reveals TECVAYLI plus DARZALEX FASPRO combination significantly improves PFS and overall survival

According to Johnson & Johnson, results of the Phase 3 MajesTEC-3 study reveal TECVAYLI(R) plus DARZALEX FASPRO(R) combination significantly improves PFS and overall su . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products